---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106932"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:50:35.943286+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics Q2 2025 net loss $6.1M; cash $29.8M; FDA decision on COYA 302 ALS IND by Aug 29

## Summary
- Net loss $6.1M vs $2.9M in Q2 2024; collaboration revenue fell to $0.2M from $3.4M.
- Cash and equivalents $29.8M as of June 30, 2025.
- R&D expenses $3.7M (down $0.9M YoY); G&A $2.9M (up $0.8M YoY).
- FDA decision on IND for COYA 302 in ALS expected by August 29, 2025; upon acceptance, DRL milestone payment of $8.4M.
- Additional catalysts: top-line data from FTD trial, IND for FTD by year-end.

## SEC filing metadata
- accession: 0000950170-25-106932
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017025106932/0000950170-25-106932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017025106932/coya-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106932
- JSON: https://secwatch.observer/filing/0000950170-25-106932.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106932.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.